<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12639">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467389</url>
  </required_header>
  <id_info>
    <org_study_id>NEUA-014-05S</org_study_id>
    <nct_id>NCT00467389</nct_id>
  </id_info>
  <brief_title>Use of Donepezil for Treatment of Cocaine Dependence</brief_title>
  <official_title>Donepezil Effects on Cocaine Craving and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of intravenous cocaine in subjects
      receiving oral donepezil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, double-dummy, placebo controlled, inpatient,
      single-center, parallel group evaluation of the potential for oral donepezil to attenuate
      cocaine-induced craving. Non-treatment-seeking cocaine-experienced volunteers will receive
      baseline treatment with intravenous cocaine (30Mg). Forty-two subjects that tolerate
      baseline cocaine infusions will then receive two subsequent intravenous doses of cocaine
      during double-blind treatment with oral placebo or 5 mg daily of donepezil. Each dose of
      cocaine will be preceded or followed by administration of intravenous placebo (saline) in a
      random order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cocaine Safety in Subjects Receiving Donepezil</measure>
    <time_frame>Two weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients evaluated for clinical and laboratory adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cocaine Subjective Effects</measure>
    <time_frame>3 to 30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cocaine Induced 'High' by VAS (visual analogue scale, between 3 and 30 minutes after intravenous dosing, in mm). VAS results ranged from 0 (minimum effect) to 100 (maximum effect).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine Pharmacokinetics</measure>
    <time_frame>0 to 8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area-Under-the-Curve for Plasma Concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cocaine Abuse and Dependence</condition>
  <arm_group>
    <arm_group_label>Oral Placebo First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil, 5 mg daily</intervention_name>
    <description>This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.</description>
    <arm_group_label>Oral Placebo First</arm_group_label>
    <arm_group_label>Donepezil First</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>Inactive Comparator with Similar Appearance to Active Medication</description>
    <arm_group_label>Oral Placebo First</arm_group_label>
    <arm_group_label>Donepezil First</arm_group_label>
    <other_name>Inactive Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-treatment seeking, experienced cocaine users, who have used cocaine by smoking or
             intravenous injection within the four weeks prior to screening, and must supply a
             cocaine-positive urine obtained within four weeks of entry into the study.

        Exclusion Criteria:

          -  Shows signs of psychostimulant toxicity, or has a history of a medical adverse
             reaction to cocaine or other psychostimulants, including loss of consciousness, chest
             pain, cardiac ischemia, or seizure.

          -  Has a current psychiatric disorder other than drug abuse or dependence or dementia.

          -  Meets the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for
             dependence to opiates, benzodiazepines, alcohol, or other sedative-hypnotics.

          -  Has received opiate-substitution therapy (methadone or buprenorphine) within two
             months prior to enrollment.

          -  Has current or past history of seizure disorder, including alcohol- or
             psychostimulant- related seizures, or family history of seizure disorder.

          -  Has a diagnosis of adult asthma, or chronic obstructive pulmonary disease, including
             a history of acute asthma within the past two years, and those with current or recent
             (with the past two years) treatment with an inhaled or oral beta-adrenergic agonist.

          -  Has had head trauma that resulted in neurological sequelae.

          -  Has an unstable medical condition, which, in the judgement of investigators, would
             make participation hazardous.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Grasing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Office of Research and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grasing K, Mathur D, Newton TF, DeSouza C. Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug Alcohol Depend. 2010 Feb 1;107(1):69-75. doi: 10.1016/j.drugalcdep.2009.09.010.</citation>
    <PMID>19836169</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>April 27, 2007</firstreceived_date>
  <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetylcholine</keyword>
  <keyword>Acetylcholinesterase</keyword>
  <keyword>Butyrylcholinesterase</keyword>
  <keyword>Cholinesterase Inhibitor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Treatment First</title>
          <description>Participants initially treated with oral placebo, and later treated with oral donepezil</description>
        </group>
        <group group_id="P2">
          <title>Donepezil Treatment First</title>
          <description>Participants initially treated with oral donepezil, and later treated with oral placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participating subjects</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All recruited subjects</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.4" spread="0.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Safety in Subjects Receiving Donepezil</title>
        <description>Patients evaluated for clinical and laboratory adverse events</description>
        <time_frame>Two weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants included</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Treatment Period</title>
            <description>Inactive Comparator</description>
          </group>
          <group group_id="O2">
            <title>Donepezil Treatment Period</title>
            <description>Active Treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cocaine Safety in Subjects Receiving Donepezil</title>
            <description>Patients evaluated for clinical and laboratory adverse events</description>
            <units>Participants with an Adverse Event</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Subjective Effects</title>
        <description>Cocaine Induced 'High' by VAS (visual analogue scale, between 3 and 30 minutes after intravenous dosing, in mm). VAS results ranged from 0 (minimum effect) to 100 (maximum effect).</description>
        <time_frame>3 to 30 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo Treatment Period</title>
            <description>Inactive Comparator</description>
          </group>
          <group group_id="O2">
            <title>Donepezil Treatment Period</title>
            <description>Active Treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cocaine Subjective Effects</title>
            <description>Cocaine Induced 'High' by VAS (visual analogue scale, between 3 and 30 minutes after intravenous dosing, in mm). VAS results ranged from 0 (minimum effect) to 100 (maximum effect).</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44.1" spread="17.8"/>
                  <measurement group_id="O2" value="89.9" spread="35.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Pharmacokinetics</title>
        <description>Area-Under-the-Curve for Plasma Concentration</description>
        <time_frame>0 to 8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo Treatment Period</title>
            <description>Inactive Comparator</description>
          </group>
          <group group_id="O2">
            <title>Donepezil Treatment Period</title>
            <description>Active Treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cocaine Pharmacokinetics</title>
            <description>Area-Under-the-Curve for Plasma Concentration</description>
            <units>ng-hr/ml</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34,503" spread="3,599"/>
                  <measurement group_id="O2" value="40,812" spread="5,244"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Treatment Period</title>
          <description>Inactive Comparator.</description>
        </group>
        <group group_id="E2">
          <title>Donepezil Treatment Period</title>
          <description>Active Treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Nausea</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal distress</sub_title>
                <description>One patient experienced a single episode of nausea and vomiting on his second day of treatment with donepezil that resolved spontaneously.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title vocab="Discomfort">Chest discomfort</sub_title>
                <description>An additional patient reported 5 minutes of mild chest discomfort that he attributed to eating too much during his third day of donepezil treatment, with no electrocardiogram changes observed.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth Grasing</name_or_title>
      <organization>Substance Abuse Research Laboratory, Kansas City VA Medical Center</organization>
      <phone>(816) 922-2756</phone>
      <email>kenneth.grasing@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
